Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: A prospective multicenter trial

Lauri M. Burroughs, Eneida Nemecek, Troy R. Torgerson, Barry E. Storer, Julie An Talano, Jennifer Domm, Roger H. Giller, Akiko Shimamura, Colleen Delaney, Suzanne Skoda-Smith, Monica S. Thakar, K. Scott Baker, David J. Rawlings, Janet A. Englund, Mary E D Flowers, H. Joachim Deeg, Rainer Storb, Ann E. Woolfrey

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Hematopoietic cell transplantation is an effective treatment for patients with nonmalignant diseases and for many is the only known cure. Conventional myeloablative regimens have been associated with unacceptably high early transplant-related mortality (TRM), particularly in patients with comorbid conditions. This prospective multicenter trial was designed to determine the safety and engraftment efficacy of treosulfan-based conditioning in patients with nonmalignant diseases. Thirty-one patients received HLA-matched related (n=4) or unrelated (n=27) grafts after conditioning with treosulfan (total dose, 42g/m2), fludarabine (total dose, 150mg/m2), ± thymoglobulin (6mg/kg; n=22). Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus and methotrexate. All patients engrafted. Day-100 TRM was 0%. With a median follow-up of 2years, the 2-year survival was 90%. Three patients died of GVHD, recurrent hemophagocytic lymphohistiocytosis, and a surgical complication, respectively. The cumulative incidences of grades II to IV and III to IV acute GVHD at day 100 and chronic GVHD at 2years were 62%, 10%, and 21%, respectively. Patients who received thymoglobulin had a significantly lower incidence of grades III to IV acute GVHD (0% versus 33%; P=.005). These results indicate that the combination of treosulfan, fludarabine, and thymoglobulin is effective at establishing donor engraftment with low toxicity and improved survival in patients with nonmalignant diseases and support the need for future disease-specific clinical trials.

Original languageEnglish (US)
Pages (from-to)1996-2003
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume20
Issue number12
DOIs
StatePublished - Dec 1 2014

Fingerprint

treosulfan
Cell Transplantation
Multicenter Studies
Graft vs Host Disease
Transplants
Hemophagocytic Lymphohistiocytosis
Survival
Mortality
Incidence
Tacrolimus
Methotrexate

Keywords

  • Allo-transplantation
  • Clinical results in inherited disorders
  • Conditioning regimen
  • Nonmalignant diseases
  • Reduced-intensity conditioning

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases : A prospective multicenter trial. / Burroughs, Lauri M.; Nemecek, Eneida; Torgerson, Troy R.; Storer, Barry E.; Talano, Julie An; Domm, Jennifer; Giller, Roger H.; Shimamura, Akiko; Delaney, Colleen; Skoda-Smith, Suzanne; Thakar, Monica S.; Baker, K. Scott; Rawlings, David J.; Englund, Janet A.; Flowers, Mary E D; Deeg, H. Joachim; Storb, Rainer; Woolfrey, Ann E.

In: Biology of Blood and Marrow Transplantation, Vol. 20, No. 12, 01.12.2014, p. 1996-2003.

Research output: Contribution to journalArticle

Burroughs, LM, Nemecek, E, Torgerson, TR, Storer, BE, Talano, JA, Domm, J, Giller, RH, Shimamura, A, Delaney, C, Skoda-Smith, S, Thakar, MS, Baker, KS, Rawlings, DJ, Englund, JA, Flowers, MED, Deeg, HJ, Storb, R & Woolfrey, AE 2014, 'Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: A prospective multicenter trial', Biology of Blood and Marrow Transplantation, vol. 20, no. 12, pp. 1996-2003. https://doi.org/10.1016/j.bbmt.2014.08.020
Burroughs, Lauri M. ; Nemecek, Eneida ; Torgerson, Troy R. ; Storer, Barry E. ; Talano, Julie An ; Domm, Jennifer ; Giller, Roger H. ; Shimamura, Akiko ; Delaney, Colleen ; Skoda-Smith, Suzanne ; Thakar, Monica S. ; Baker, K. Scott ; Rawlings, David J. ; Englund, Janet A. ; Flowers, Mary E D ; Deeg, H. Joachim ; Storb, Rainer ; Woolfrey, Ann E. / Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases : A prospective multicenter trial. In: Biology of Blood and Marrow Transplantation. 2014 ; Vol. 20, No. 12. pp. 1996-2003.
@article{9b1fc7892705424690648d6ea0378b90,
title = "Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: A prospective multicenter trial",
abstract = "Hematopoietic cell transplantation is an effective treatment for patients with nonmalignant diseases and for many is the only known cure. Conventional myeloablative regimens have been associated with unacceptably high early transplant-related mortality (TRM), particularly in patients with comorbid conditions. This prospective multicenter trial was designed to determine the safety and engraftment efficacy of treosulfan-based conditioning in patients with nonmalignant diseases. Thirty-one patients received HLA-matched related (n=4) or unrelated (n=27) grafts after conditioning with treosulfan (total dose, 42g/m2), fludarabine (total dose, 150mg/m2), ± thymoglobulin (6mg/kg; n=22). Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus and methotrexate. All patients engrafted. Day-100 TRM was 0{\%}. With a median follow-up of 2years, the 2-year survival was 90{\%}. Three patients died of GVHD, recurrent hemophagocytic lymphohistiocytosis, and a surgical complication, respectively. The cumulative incidences of grades II to IV and III to IV acute GVHD at day 100 and chronic GVHD at 2years were 62{\%}, 10{\%}, and 21{\%}, respectively. Patients who received thymoglobulin had a significantly lower incidence of grades III to IV acute GVHD (0{\%} versus 33{\%}; P=.005). These results indicate that the combination of treosulfan, fludarabine, and thymoglobulin is effective at establishing donor engraftment with low toxicity and improved survival in patients with nonmalignant diseases and support the need for future disease-specific clinical trials.",
keywords = "Allo-transplantation, Clinical results in inherited disorders, Conditioning regimen, Nonmalignant diseases, Reduced-intensity conditioning",
author = "Burroughs, {Lauri M.} and Eneida Nemecek and Torgerson, {Troy R.} and Storer, {Barry E.} and Talano, {Julie An} and Jennifer Domm and Giller, {Roger H.} and Akiko Shimamura and Colleen Delaney and Suzanne Skoda-Smith and Thakar, {Monica S.} and Baker, {K. Scott} and Rawlings, {David J.} and Englund, {Janet A.} and Flowers, {Mary E D} and Deeg, {H. Joachim} and Rainer Storb and Woolfrey, {Ann E.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.bbmt.2014.08.020",
language = "English (US)",
volume = "20",
pages = "1996--2003",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases

T2 - A prospective multicenter trial

AU - Burroughs, Lauri M.

AU - Nemecek, Eneida

AU - Torgerson, Troy R.

AU - Storer, Barry E.

AU - Talano, Julie An

AU - Domm, Jennifer

AU - Giller, Roger H.

AU - Shimamura, Akiko

AU - Delaney, Colleen

AU - Skoda-Smith, Suzanne

AU - Thakar, Monica S.

AU - Baker, K. Scott

AU - Rawlings, David J.

AU - Englund, Janet A.

AU - Flowers, Mary E D

AU - Deeg, H. Joachim

AU - Storb, Rainer

AU - Woolfrey, Ann E.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Hematopoietic cell transplantation is an effective treatment for patients with nonmalignant diseases and for many is the only known cure. Conventional myeloablative regimens have been associated with unacceptably high early transplant-related mortality (TRM), particularly in patients with comorbid conditions. This prospective multicenter trial was designed to determine the safety and engraftment efficacy of treosulfan-based conditioning in patients with nonmalignant diseases. Thirty-one patients received HLA-matched related (n=4) or unrelated (n=27) grafts after conditioning with treosulfan (total dose, 42g/m2), fludarabine (total dose, 150mg/m2), ± thymoglobulin (6mg/kg; n=22). Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus and methotrexate. All patients engrafted. Day-100 TRM was 0%. With a median follow-up of 2years, the 2-year survival was 90%. Three patients died of GVHD, recurrent hemophagocytic lymphohistiocytosis, and a surgical complication, respectively. The cumulative incidences of grades II to IV and III to IV acute GVHD at day 100 and chronic GVHD at 2years were 62%, 10%, and 21%, respectively. Patients who received thymoglobulin had a significantly lower incidence of grades III to IV acute GVHD (0% versus 33%; P=.005). These results indicate that the combination of treosulfan, fludarabine, and thymoglobulin is effective at establishing donor engraftment with low toxicity and improved survival in patients with nonmalignant diseases and support the need for future disease-specific clinical trials.

AB - Hematopoietic cell transplantation is an effective treatment for patients with nonmalignant diseases and for many is the only known cure. Conventional myeloablative regimens have been associated with unacceptably high early transplant-related mortality (TRM), particularly in patients with comorbid conditions. This prospective multicenter trial was designed to determine the safety and engraftment efficacy of treosulfan-based conditioning in patients with nonmalignant diseases. Thirty-one patients received HLA-matched related (n=4) or unrelated (n=27) grafts after conditioning with treosulfan (total dose, 42g/m2), fludarabine (total dose, 150mg/m2), ± thymoglobulin (6mg/kg; n=22). Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus and methotrexate. All patients engrafted. Day-100 TRM was 0%. With a median follow-up of 2years, the 2-year survival was 90%. Three patients died of GVHD, recurrent hemophagocytic lymphohistiocytosis, and a surgical complication, respectively. The cumulative incidences of grades II to IV and III to IV acute GVHD at day 100 and chronic GVHD at 2years were 62%, 10%, and 21%, respectively. Patients who received thymoglobulin had a significantly lower incidence of grades III to IV acute GVHD (0% versus 33%; P=.005). These results indicate that the combination of treosulfan, fludarabine, and thymoglobulin is effective at establishing donor engraftment with low toxicity and improved survival in patients with nonmalignant diseases and support the need for future disease-specific clinical trials.

KW - Allo-transplantation

KW - Clinical results in inherited disorders

KW - Conditioning regimen

KW - Nonmalignant diseases

KW - Reduced-intensity conditioning

UR - http://www.scopus.com/inward/record.url?scp=84912123151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912123151&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2014.08.020

DO - 10.1016/j.bbmt.2014.08.020

M3 - Article

C2 - 25196857

AN - SCOPUS:84912123151

VL - 20

SP - 1996

EP - 2003

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 12

ER -